Cite
S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.
MLA
Li, Yu Hong, et al. “S-1 plus Cisplatin versus Fluorouracil plus Cisplatin in Advanced Gastric or Gastro-Esophageal Junction Adenocarcinoma Patients: A Pilot Study.” Oncotarget, vol. 6, no. 33, Oct. 2015, pp. 35107–15. EBSCOhost, https://doi.org/10.18632/oncotarget.5959.
APA
Li, Y. H., Qiu, M. Z., Xu, J. M., Sun, G. P., Lu, H. S., Liu, Y. P., Zhong, M. Z., Zhang, H. L., Yu, S. Y., Li, W., Hu, X. H., Wang, J. J., Cheng, Y., Zhou, J. T., Guo, Z. Q., Guan, Z. G., & Xu, R. H. (2015). S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget, 6(33), 35107–35115. https://doi.org/10.18632/oncotarget.5959
Chicago
Li, Yu Hong, Miao Zhen Qiu, Jian Ming Xu, Guo Ping Sun, Hui Shan Lu, Yun Peng Liu, Mei Zuo Zhong, et al. 2015. “S-1 plus Cisplatin versus Fluorouracil plus Cisplatin in Advanced Gastric or Gastro-Esophageal Junction Adenocarcinoma Patients: A Pilot Study.” Oncotarget 6 (33): 35107–15. doi:10.18632/oncotarget.5959.